GlassScriptPhysician profile
Aaron M Mulhall
NPI 1801113576
$14,450.38
in general payments reported to CMS, 2019-2025
40 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,134 · 2020: $660 · 2021: $278 · 2022: $708 · 2023: $7,194 · 2024: $903 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,424 · Food and Beverage: $1,611 · Travel and Lodging: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,423.99 |
| Food and Beverage | $1,610.59 |
| Travel and Lodging | $635.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,175.31 | 2022-2024 | Da Vinci Surgical System, Ion |
| Astrazeneca Pharmaceuticals LP | $3,414.47 | 2019-2025 | Fasenra, Tagrisso, Airsupra |
| Insmed, INC. | $880.87 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.59 | 2019-2024 | Ofev |
| Grifols USA, LLC | $316.90 | 2019-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $251.55 | 2019-2021 | |
| Glaxosmithkline, LLC. | $243.77 | 2019-2025 | Nucala, Trelegy Ellipta |
| Ethicon INC. | $217.38 | 2022 | |
| Genentech USA, INC. | $155.59 | 2019-2024 | Xolair |
| United Therapeutics Corporation | $151.15 | 2019-2025 | Tyvaso, Tyvaso |
| Astellas Pharma US INC | $126.74 | 2019-2024 | Cresemba |
| Mayne Pharma Commercial LLC | $101.53 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $96.80 | 2019-2024 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $91.59 | 2019-2022 | |
| Genzyme Corporation | $84.32 | 2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $70.83 | 2021-2025 | Aralast, Glassia |
| Csl Behring | $63.93 | 2019-2024 | Kcentra |
| Baxter Healthcare | $62.22 | 2022-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Teva Pharmaceuticals USA, INC. | $52.53 | 2019-2022 | |
| Amgen INC. | $51.87 | 2019-2024 | Tezspire |
| Siemens Medical Solutions USA, INC. | $45.10 | 2024 | Cios Spin |
| Galvanize Therapeutics, INC | $36.43 | 2024 | Aliya System |
| Viatris Specialty LLC | $35.37 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $34.78 | 2019-2024 | Dupixent |
| Tactile Systems Technology INC | $32.75 | 2025 | Flexitouch Plus, Nimbl |
| Boston Scientific Corporation | $32.74 | 2024 | Ekosonic |
| Bayer Healthcare Pharmaceuticals INC. | $30.92 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $28.51 | 2024-2025 | Capvaxive, Gardasil 9 |
| Pfizer INC. | $27.77 | 2019-2020 | |
| Philips North America LLC | $19.30 | 2025 | Vest Therapy Und |
| Mallinckrodt Hospital Products INC. | $17.59 | 2021 | |
| Shire North American Group INC | $16.77 | 2019 | |
| Verona Pharma, INC. | $16.70 | 2025 | Ohtuvayre |
| Circassia INC. | $16.62 | 2020 | |
| Ambu INC. | $13.00 | 2023 | |
| Tetraphase Pharmaceuticals, INC. | $11.97 | 2019 | |
| Allergan, INC. | $11.85 | 2019 | |
| Pulmonx Corporation | $11.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Mulhall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.